Profile data is unavailable for this security.
About the company
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
- Revenue in SEK (TTM)9.29m
- Net income in SEK-77.34m
- Incorporated1983
- Employees15.00
- LocationIntervacc ABVastertorpsvagen 135HAGERSTEN 129 44SwedenSWE
- Phone+46 812010600
- Fax+46 812010640
- Websitehttp://intervacc.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NextCell Pharma AB | 10.66m | -41.96m | 128.64m | 24.00 | -- | 1.90 | -- | 12.06 | -0.8409 | -0.8409 | 0.2095 | 0.9249 | 0.1254 | 55.56 | 5.31 | 444,362.90 | -49.33 | -35.01 | -55.89 | -37.45 | -247.97 | -304.79 | -393.45 | -468.52 | 6.09 | -- | 0.00 | -- | 5.45 | 42.54 | -5.40 | -- | -27.06 | -- |
| Kancera AB | 0.00 | -53.07m | 130.64m | 5.00 | -- | 1.57 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Biovica International AB | 7.25m | -115.45m | 151.33m | 27.00 | -- | 1.69 | -- | 20.87 | -1.73 | -1.73 | 0.1055 | 1.06 | 0.0584 | 17.30 | 4.76 | 226,593.80 | -92.98 | -51.94 | -110.37 | -58.18 | -394.72 | -576.01 | -1,592.15 | -2,217.41 | 3.47 | -- | 0.0721 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Acousort AB | 3.44m | -19.30m | 170.25m | -- | -- | 11.13 | -- | 49.51 | -1.33 | -1.33 | 0.2379 | 1.02 | 0.1461 | 4.08 | 1.96 | -- | -81.99 | -48.62 | -137.70 | -69.77 | -159.41 | -68.05 | -561.21 | -299.58 | 1.91 | -- | 0.00 | -- | 11.51 | 38.81 | -24.01 | -- | -- | -- |
| Biosergen AB | 0.00 | -23.42m | 170.97m | 2.00 | -- | 7.49 | -- | -- | -0.2273 | -0.2273 | 0.00 | 0.0822 | 0.00 | -- | -- | 0.00 | -179.89 | -- | -244.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -54.78m | 182.68m | 12.00 | -- | 10.49 | -- | -- | -1.66 | -1.66 | 0.00 | 0.5435 | 0.00 | -- | -- | -- | -130.29 | -40.21 | -170.98 | -45.67 | -- | -- | -- | -- | -- | -- | 0.0502 | -- | -- | -- | -20.52 | -- | -- | -- |
| Intervacc AB | 9.29m | -77.34m | 192.37m | 15.00 | -- | 1.07 | -- | 20.72 | -1.02 | -1.02 | 0.1226 | 2.38 | 0.0386 | 5.09 | 1.59 | 619,066.70 | -32.15 | -17.62 | -35.27 | -18.77 | -432.03 | -243.59 | -832.82 | -626.90 | 2.26 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| ViroGates A/S | 6.52m | -20.56m | 198.30m | 10.00 | -- | 15.00 | -- | 30.40 | -5.64 | -5.64 | 0.8338 | 1.10 | 0.2935 | 0.4667 | 3.62 | 419,900.00 | -92.50 | -46.58 | -105.88 | -52.09 | 57.25 | 77.91 | -315.15 | -238.01 | 6.13 | -19.84 | 0.4278 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| Xintela AB | 381.00k | -40.83m | 200.20m | -- | -- | -- | -- | 525.47 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| SenzaGen AB | -100.00bn | -100.00bn | 206.53m | 33.00 | -- | 2.31 | -- | -- | -- | -- | -- | 3.03 | -- | -- | -- | -- | -- | -25.84 | -- | -29.85 | -- | 68.62 | -- | -132.29 | 3.18 | -- | 0.0225 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
| Lifecare ASA | 15.06m | -59.78m | 208.26m | 32.00 | -- | 0.1789 | -- | 13.83 | -16.49 | -16.49 | 1.51 | 73.51 | 0.1698 | -- | 1.56 | 471,007.80 | -67.36 | -40.00 | -86.96 | -45.26 | -- | -- | -396.68 | -175.53 | -- | -- | 0.1102 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Abliva AB | 137.00k | -102.13m | 217.60m | 6.00 | -- | 2.12 | -- | 1,588.35 | -0.0928 | -0.0928 | 0.0001 | 0.0638 | 0.0013 | -- | 0.0062 | 22,833.33 | -93.81 | -74.59 | -103.87 | -86.98 | -35,826.28 | -- | -74,542.34 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Guard Therapeutics Intrntnl AB (publ) | 0.00 | -87.20m | 248.36m | 6.00 | -- | 3.85 | -- | -- | -8.16 | -8.16 | 0.00 | 5.25 | 0.00 | -- | -- | -- | -96.71 | -69.56 | -117.53 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.45m | 250.50m | 4.00 | -- | 9.99 | -- | -- | -0.1734 | -0.1734 | 0.00 | 0.0471 | 0.00 | -- | -- | 0.00 | -235.29 | -125.42 | -407.84 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -62.30m | 251.25m | 13.00 | -- | 2.36 | -- | -- | -1.12 | -1.12 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -46.53 | -- | -56.96 | -- | -- | -- | -- | -- | -- | -10.21 | 0.1983 | -- | -- | -- | 16.72 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Intervacc AB's reporting currency: Swedish Krona SEK
22.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 30 Jun 2023 | 5.13m | 6.77% |
| Handelsbanken Fonder ABas of 30 Jun 2023 | 4.57m | 6.03% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 3.75m | 4.95% |
| Aktia Bank Plc (Investment Management)as of 31 Dec 2023 | 1.16m | 1.53% |
| Nordea Investment Management ABas of 31 Dec 2023 | 1.12m | 1.48% |
| Aktie-Ansvar ABas of 31 Dec 2023 | 1.05m | 1.39% |
| Alpcot Capital Management Ltd.as of 31 Oct 2024 | 105.00k | 0.14% |
| FCG Fonder ABas of 31 Oct 2024 | 15.04k | 0.02% |
| Cicero Fonder ABas of 31 Mar 2023 | 11.51k | 0.02% |
| Deka Investment GmbHas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
